This means the company is now cleared to reveal the biomarker: anterior gradient protein 2 (AGR2). HealthLinx says its performance will be further tested in a forthcoming international biomarker study ...

COLUMBUS, Ohio, March 02, 2022 (GLOBE NEWSWIRE) -- Walden University and HealthLinx are jointly providing a 2022 Magnet Program Director virtual workshop, "Spring Training for Magnet Program Directors ...

You have reached your maximum number of saved items. Remove items from your saved list to add more. Drug developer HealthLinx Ltd has secured $7.23 million to help it commercialise its ovarian cancer ...

Encapsulation technology, IMMUPEL, by Living Cell Technologies (ASX:LCT) has received an Australian patent , while HealthLinx (ASX:HTX) has received a UK patent for its OvPlex diagnostic technology.

The nursing excellence workshop will provide hospital leaders with a deep dive into the details required for their organization's process towards successful designation The workshop will feature ...

Diagnostics developer Healthlinx Ltd hopes to have a multi-marker blood test for ovarian cancer on the market in the second quarter of calendar 2008, after successfully completing a Phase II ...

MELBOURNE, Australia--(BUSINESS WIRE)--HealthLinx Limited (ASX:HTX) today announced the signing of a joint patent agreement with Bruker Daltonics Inc. to further develop biomarkers that have been ...

Junior biotechnology company HealthLinx has secured up to $750,000 over the next 24 months after executing its Victorian Science Agenda Investment Fund grant agreement. Junior biotechnology company ...

Shares of Australia's HealthLinx shot up after the biotech announced that its diagnostic test for ovarian cancer outperformed the diagnostic tool now in use. Investigators said that OvPlex ...

Junior biotechnology company Healthlinx believes it is on track to develop by the second quarter of 2008 one of the first ovarian cancer diagnostics on the market. The company recently signed a deal ...